Drug
Voxelotor clinical trials
Also written GBT440 and Oxbryta.
- studies test it
- 26
- open now
- 1
- in phase 3
- 5
- first study started
- 2014
Keep track of what changes. Save the voxelotor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 7 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 10
- Phase 3
- 5
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 6
Pfizer (11) · Global Blood Therapeutics (9) · Inova Health Care Services (1) · Elizabeth Yang, MD, PhD (1) · Assistance Publique - Hôpitaux de Paris (1) · Emory University (1) · University of Illinois at Chicago (1) · Duke University (1)
Studies
Open first, then newest update. How each study uses voxelotor is read from its arms, and is right about nine times in ten.
Testing it · 26
- Hemolysis Related Complications in SCD. A Phase II Study With VoxelotorRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05199766Written as Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease
- Assessing Physical Function in Sickle Cell Patients Taking VoxelotorCompletedPhase 2Inova Health Care ServicesNCT06023199Written as Voxelotor
- Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell DiseaseTerminatedPhase 3PfizerNCT04218084Written as Voxelotor
- The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell AnemiaTerminatedPhase 2Emory UniversityNCT05018728Written as Voxelotor
- Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031TerminatedPhase 3PfizerNCT03573882Written as Voxelotor
- Open-Label Extension of VoxelotorTerminatedPhase 3PfizerNCT04188509Written as Voxelotor
- Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseTerminatedPhase 2PfizerNCT02850406Written as Voxelotor
- Resolution of Sickle Cell Leg Ulcers With VoxelotorTerminatedPhase 3PfizerNCT05561140Written as Voxelotor Oral Tablet
- A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney DiseaseTerminatedPhase 1/2University of Illinois at ChicagoNCT04335721Written as Voxelotor
- Voxelotor CYP and Transporter Cocktail Interaction StudyCompletedPhase 1PfizerNCT05981365Written as Voxelotor
- Voxelotor Brain Oxygenation and Neurocognitive StudyWithdrawnPhase 4PfizerNCT05228821Written as Voxelotor Oral Tablet
- Voxelotor for Improving Oxygen Saturation in AdultsTerminatedPhase 2Duke UniversityNCT05289570Written as Voxelotor
- Actigraphy Improvement With Voxelotor (ActIVe) StudyCompletedPhase 4PfizerNCT04400487Written as Voxelotor
- Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCDTerminatedPhase 2PfizerNCT04247594Written as Voxelotor
- Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)CompletedPhase 3PfizerNCT03036813Written as voxelotor
- Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic ImpairmentCompletedPhase 1PfizerNCT03114540Written as GBT440
- Voxelotor Sickle Cell Exercise StudyCompletedPhase 4Elizabeth Yang, MD, PhDNCT04581356Written as Voxelotor
- Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPFCompletedPhase 2Global Blood TherapeuticsNCT02846324Written as GBT440
- Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at RestTerminatedPhase 2Global Blood TherapeuticsNCT02989168Written as GBT440
- Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic ConditionsTerminatedPhase 1Global Blood TherapeuticsNCT03051711Written as GBT440
Codes
What other systems call voxelotor · ClinicalTrials.gg INT001003
- MeSH (NLM) C000628792voxelotorConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3ZO554A4Q8VOXELOTORConfirmed FDA, NLM, Wikidata
- RxNorm 2265678One source FDA
- Wikidata Q60761545voxelotorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152089VoxelotorOne source FDA
- DrugBank DB14975One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628792 | voxelotor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3ZO554A4Q8 | VOXELOTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2265678 | — | One source FDA |
| Wikidata | Q60761545 | voxelotor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152089 | Voxelotor | One source FDA |
| DrugBank | DB14975 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.